11:32 AM EST - Medicenna Therapeutics Corp. : Announced a clinical update on the monotherapy dose escalation portion of the first-in-human, Phase 1/2 ABILITY Study in patients with advanced solid tumors, as its drug candidate MDNA11, a beta-only, long-acting IL-2 super-agonist, advances to the monotherapy dose expansion phase. Medicenna Therapeutics Corp.
shares T.MDNA are trading down $0.04 at $0.52.
